1. Home
  2. NVTS vs PTGX Comparison

NVTS vs PTGX Comparison

Compare NVTS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navitas Semiconductor Corporation

NVTS

Navitas Semiconductor Corporation

HOLD

Current Price

$22.08

Market Cap

7.3B

Sector

Technology

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$110.79

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVTS
PTGX
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
6.4B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
NVTS
PTGX
Price
$22.08
$110.79
Analyst Decision
Buy
Strong Buy
Analyst Count
5
13
Target Price
$6.68
$108.23
AVG Volume (30 Days)
33.7M
521.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
$45,916,000.00
N/A
Revenue This Year
N/A
$874.25
Revenue Next Year
$71.28
N/A
P/E Ratio
N/A
$2,249.20
Revenue Growth
N/A
N/A
52 Week Low
$5.44
$49.86
52 Week High
$34.17
$112.77

Technical Indicators

Market Signals
Indicator
NVTS
PTGX
Relative Strength Index (RSI) 48.18 60.67
Support Level $7.35 $94.48
Resistance Level $23.82 N/A
Average True Range (ATR) 2.95 4.98
MACD -0.95 1.48
Stochastic Oscillator 13.81 84.24

Price Performance

Historical Comparison
NVTS
PTGX

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: